EP4705341A1 - Kombinationen zur behandlung von krebs - Google Patents

Kombinationen zur behandlung von krebs

Info

Publication number
EP4705341A1
EP4705341A1 EP24724206.8A EP24724206A EP4705341A1 EP 4705341 A1 EP4705341 A1 EP 4705341A1 EP 24724206 A EP24724206 A EP 24724206A EP 4705341 A1 EP4705341 A1 EP 4705341A1
Authority
EP
European Patent Office
Prior art keywords
cancer
treatment
tinostamustine
combination
immune checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24724206.8A
Other languages
English (en)
French (fr)
Inventor
Markus JÖRGER
Lukas Flatz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of EP4705341A1 publication Critical patent/EP4705341A1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24724206.8A 2023-05-05 2024-05-03 Kombinationen zur behandlung von krebs Pending EP4705341A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU504140 2023-05-05
PCT/EP2024/062307 WO2024231293A1 (en) 2023-05-05 2024-05-03 Combinations for treating cancer

Publications (1)

Publication Number Publication Date
EP4705341A1 true EP4705341A1 (de) 2026-03-11

Family

ID=86604017

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24724206.8A Pending EP4705341A1 (de) 2023-05-05 2024-05-03 Kombinationen zur behandlung von krebs

Country Status (2)

Country Link
EP (1) EP4705341A1 (de)
WO (1) WO2024231293A1 (de)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US645A (en) 1838-03-17 Back for poeges and fetrnages
US5376A (en) 1847-11-20 Improvement in bog-cutters
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
WO1998056422A1 (en) 1997-06-13 1998-12-17 The University Of Kansas Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
DK2389375T3 (en) 2009-01-23 2015-08-24 Euro Celtique Sa Hydroxamsyrederivater
US9604104B2 (en) * 2015-08-27 2017-03-28 Roka Sports, Inc. Goggles with retroscopic lens angle for enhanced forward vision
RU2018130831A (ru) * 2016-01-28 2020-03-02 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии
TWI808055B (zh) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療

Also Published As

Publication number Publication date
WO2024231293A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
US11446377B2 (en) Anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
US20190290619A1 (en) Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
US20160243228A1 (en) Methods, compositions, and kits for treatment of cancer
CN110869765A (zh) 组合疗法
US12403154B2 (en) Administration of sting agonist and checkpoint inhibitors
JP2019526595A (ja) 血液癌を治療するための抗ｃｄ２０抗体、ｐｉ３キナーゼ−デルタ阻害剤および抗ｐｄ−１抗体または抗ｐｄ−ｌ１抗体の組み合わせ
KR20190141666A (ko) 항-axl 항체-약물 접합체로의 병용 요법
EP4236960A1 (de) Kombination eines ahr-hemmers mit einem pdx-hemmer oder doxorubicin
US20190160148A1 (en) Combination of pembrolizumab and abemaciclib for the treatment of cancer
CN114302746A (zh) 包含抗cd25抗体药物缀合物和另一剂的组合疗法
CN114302745A (zh) 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
US20240366569A1 (en) Combinations for treating cancer
BR112021000169A2 (pt) Ministração de inibidor de enzima ativadora de sumo e anticorpos anti-cd20
EP3930719B1 (de) Verabreichung von sumo-aktivierendem enzyminhibitor und checkpoint-inhibitoren
TW202233206A (zh) Ｓｔｉｎｇ促效劑、檢查點抑制劑及輻射之投與
WO2024231293A1 (en) Combinations for treating cancer
RU2830077C2 (ru) Введение ингибитора sumo-активирующего фермента и ингибиторов контрольных точек
US20230322929A1 (en) Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy
CN121038812A (zh) 用抗btla作为联合疗法治疗实体瘤的组合和方法
CN114641298A (zh) 包含氧氮杂膦衍生物的癌症治疗用新治疗组合
CN114432438A (zh) 喹啉衍生物与pd-1单抗的药物组合
CN114470190A (zh) 喹啉衍生物与pd-1单抗的药物组合

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251203

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR